Princess Margaret Hospital, Gerry and Nancy Pencer Brain Tumour Centre
Welcome,         Profile    Billing    Logout  
 4 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mason, Warren
CATNON, NCT00626990 / 2006-001533-17: Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)

Active, not recruiting
3
751
Europe, Canada, US, RoW
temozolomide, Temodar, Temodal, DNA methylation analysis, laboratory biomarker analysis, adjuvant therapy, quality-of-life assessment, radiation therapy
European Organisation for Research and Treatment of Cancer - EORTC, NCIC Clinical Trials Group, Radiation Therapy Oncology Group, Medical Research Council, Merck Sharp & Dohme LLC
Brain and Central Nervous System Tumors
09/18
12/29
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM

Active, not recruiting
N/A
982
Europe, Canada, Japan, US, RoW
Optune®
NovoCure Ltd.
Glioblastoma Multiforme
01/26
01/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mason, Warren
CATNON, NCT00626990 / 2006-001533-17: Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)

Active, not recruiting
3
751
Europe, Canada, US, RoW
temozolomide, Temodar, Temodal, DNA methylation analysis, laboratory biomarker analysis, adjuvant therapy, quality-of-life assessment, radiation therapy
European Organisation for Research and Treatment of Cancer - EORTC, NCIC Clinical Trials Group, Radiation Therapy Oncology Group, Medical Research Council, Merck Sharp & Dohme LLC
Brain and Central Nervous System Tumors
09/18
12/29
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM

Active, not recruiting
N/A
982
Europe, Canada, Japan, US, RoW
Optune®
NovoCure Ltd.
Glioblastoma Multiforme
01/26
01/26

Download Options